Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

MUCOR-ADVANCE: Uniting multidisciplinary science to defeat a deadly fungus

Wurster S, Stewart AG, Gu Y, Youssef EG, John TM, Uppuluri P, Chamilos G, Filler S, Bruno V, Ibrahim AS, Kontoyiannis DP; MUCOR-ADVANCE consortium. MUCOR-ADVANCE:[...]

Greener Prescribing: A Quasi-Experimental Study of the Environmental Impact of Metronidazole Dosing Interval Optimization

Alsoubani M, Campion M, Swarup S, Lee P, Pearl A, Foong KS. Greener Prescribing: A Quasi-Experimental Study of the Environmental Impact of Metronidazole Dosing Interval[...]

Association of Estimated GFR at the Time of Peritoneal Dialysis Catheter Insertion With Dialysis-Related Complications

Dhoot A, Quinn RR, Clarke A, Armstrong S, Burdick R, Jain AK, Jassal SV, Kennealey PT, Liebman S, McCormick BB, Momciu B, Pauly RP, Perl[...]